z-logo
Premium
Immunostaining patterns of CD31 and podoplanin in previously untreated advanced oral/oropharyngeal cancer: Prognostic implications
Author(s) -
Bolzoni Villaret Andrea,
Schreiber Alberto,
Facchetti Fabio,
Fisogni Simona,
Lonardi Silvia,
Lombardi Davide,
Cocco Daniela,
Redaelli de Zinis Luca Oscar,
Nicolai Piero
Publication year - 2010
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21256
Subject(s) - lymphangiogenesis , medicine , podoplanin , cd31 , angiogenesis , cancer , oncology , head and neck cancer , immunohistochemistry , metastasis , lymphatic system , breast cancer , pathology
Abstract Background The objective of this study was to assess angiogenesis and lymphangiogenesis patterns in advanced oral/oropharyngeal cancer by immunohistochemical techniques. Methods Forty‐five patients with advanced oral/oropharyngeal cancer, treated by primary surgery between January 1996 and December 2005, were selected. All cases were followed for at least 24 months. Angiogenesis and lymphangiogenesis were evaluated with antibodies against CD31 and podoplanin, respectively. Survival outcomes were calculated by the Kaplan–Meier method, whereas univariate comparisons were obtained by log‐rank, chi‐square, and Mann–Whitney tests. Results Survival correlated with the area of peritumoral blood vessels ( p = .02), whereas the number of intratumoral lymphatics ( p = .02) correlated with the occurrence of nodal metastasis. The risk for distant metastasis correlated with the perimeter of intratumoral lymphatics ( p = .02). Conclusions Peritumoral angiogenesis presented different expression patterns between survivors and patients who died of disease. Intratumoral lymphangiogenesis was correlated with a higher risk of developing lymph node (LN) and distant metastasis. © 2009 Wiley Periodicals, Inc. Head Neck, 2010

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here